{ "asOf": "2026-06-21T10:18:42.667Z", "rule": "FDAAA 801 / 42 CFR Part 11: results due within 365 days of primary completion", "totalOverdueMatchingScope": 5860, "count": 500, "results": [ { "nctId": "NCT04498702", "title": "Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy", "sponsor": "Jiangsu Yahong Meditech Co., Ltd aka Asieris", "sponsorClass": "INDUSTRY", "phases": [ "PHASE2" ], "status": "COMPLETED", "primaryCompletion": "2017-01-18", "primaryCompletionType": "ACTUAL", "deadline": "2018-01-18", "daysOverdue": 3076, "startDate": "2014-05-13", "lastUpdate": "2020-08-13", "conditions": [ "Non-muscle Invasive Bladder Cancer" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT04498702", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT04498702?tab=results", "prov": "prov:2c3f81f99c9364b9" }, { "nctId": "NCT02205398", "title": "Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy", "sponsor": "Novartis Pharmaceuticals", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-01-20", "primaryCompletionType": "ACTUAL", "deadline": "2018-01-20", "daysOverdue": 3074, "startDate": "2014-07-28", "lastUpdate": "2019-01-22", "conditions": [ "Squamous Cell Carcinoma of Head and Neck (SCCHN)", "Metastatic Colorectal Cancer" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02205398", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02205398?tab=results", "ticker": "NVS", "cik": "0001114448", "issuer": "NOVARTIS AG", "tickerConfidence": 0.95, "prov": "prov:71bb51691382ca77" }, { "nctId": "NCT02520752", "title": "A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors", "sponsor": "Novartis Pharmaceuticals", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-01-30", "primaryCompletionType": "ACTUAL", "deadline": "2018-01-30", "daysOverdue": 3064, "startDate": "2015-12-10", "lastUpdate": "2020-12-10", "conditions": [ "cMET-dysregulated Advanced Solid Tumors" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02520752", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02520752?tab=results", "ticker": "NVS", "cik": "0001114448", "issuer": "NOVARTIS AG", "tickerConfidence": 0.95, "prov": "prov:dde175a73f5c147d" }, { "nctId": "NCT02583451", "title": "Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects", "sponsor": "Eisai Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-01-31", "primaryCompletionType": "ACTUAL", "deadline": "2018-01-31", "daysOverdue": 3063, "startDate": "2015-11", "lastUpdate": "2018-09-06", "conditions": [ "Healthy Participants" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02583451", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02583451?tab=results", "prov": "prov:20a6aa050d201504" }, { "nctId": "NCT01973868", "title": "Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination", "sponsor": "Bayer", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-01-31", "primaryCompletionType": "ACTUAL", "deadline": "2018-01-31", "daysOverdue": 3063, "startDate": "2013-11-21", "lastUpdate": "2019-04-09", "conditions": [ "Neoplasms" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT01973868", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT01973868?tab=results", "prov": "prov:6e681770a0916a1d" }, { "nctId": "NCT02122913", "title": "A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer", "sponsor": "Bayer", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02-01", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-01", "daysOverdue": 3062, "startDate": "2014-05-04", "lastUpdate": "2026-02-05", "conditions": [ "Solid Tumors Harboring NTRK Fusion" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02122913", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02122913?tab=results", "prov": "prov:76015f9998757a6f" }, { "nctId": "NCT01957735", "title": "BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors", "sponsor": "BPGbio", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02-01", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-01", "daysOverdue": 3062, "startDate": "2013-10", "lastUpdate": "2025-02-19", "conditions": [ "Metastatic Cancer", "Cancer", "Solid Tumor" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT01957735", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT01957735?tab=results", "prov": "prov:9b6292f0c7503c77" }, { "nctId": "NCT02933580", "title": "A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants", "sponsor": "Janssen Research & Development, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02-04", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-04", "daysOverdue": 3059, "startDate": "2016-10-12", "lastUpdate": "2018-03-16", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02933580", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02933580?tab=results", "prov": "prov:e1d702da776a597e" }, { "nctId": "NCT02568306", "title": "A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects", "sponsor": "Novo Nordisk A/S", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02-07", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-07", "daysOverdue": 3056, "startDate": "2015-10-05", "lastUpdate": "2018-07-13", "conditions": [ "Metabolism and Nutrition Disorder", "Obesity" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02568306", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02568306?tab=results", "ticker": "NVO", "cik": "0000353278", "issuer": "NOVO NORDISK A S", "tickerConfidence": 0.95, "prov": "prov:b678f6740dfb7000" }, { "nctId": "NCT03926455", "title": "Safety and Immunogenicity of Typhax, a Typhoid Vaccine", "sponsor": "Matrivax Research and Development Corporation", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02-15", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-15", "daysOverdue": 3048, "startDate": "2016-03-28", "lastUpdate": "2019-04-24", "conditions": [ "Typhoid Fever" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03926455", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03926455?tab=results", "prov": "prov:81fcde6170abdc84" }, { "nctId": "NCT03006367", "title": "Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD", "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02-26", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-26", "daysOverdue": 3037, "startDate": "2017-01-07", "lastUpdate": "2021-07-06", "conditions": [ "Attention Deficit Disorder With Hyperactivity" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03006367", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03006367?tab=results", "prov": "prov:5cae5e2b7238c431" }, { "nctId": "NCT03004768", "title": "Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants", "sponsor": "Bristol-Myers Squibb", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02-27", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-27", "daysOverdue": 3036, "startDate": "2017-01-26", "lastUpdate": "2018-02-12", "conditions": [ "Psoriasis" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03004768", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03004768?tab=results", "ticker": "BMY", "cik": "0000014272", "issuer": "BRISTOL MYERS SQUIBB CO", "tickerConfidence": 0.95, "prov": "prov:0d4f05fddc5aaf6b" }, { "nctId": "NCT03025022", "title": "A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects", "sponsor": "Janssen Research & Development, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02-27", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-27", "daysOverdue": 3036, "startDate": "2017-01-17", "lastUpdate": "2017-05-10", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03025022", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03025022?tab=results", "prov": "prov:4b7244c10bfc0007" }, { "nctId": "NCT02984852", "title": "Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants", "sponsor": "Janssen Scientific Affairs, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-28", "daysOverdue": 3035, "startDate": "2016-12", "lastUpdate": "2025-02-03", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02984852", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02984852?tab=results", "prov": "prov:2c5d1975e1fbada8" }, { "nctId": "NCT02998099", "title": "A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.", "sponsor": "GlycoMimetics Incorporated", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-28", "daysOverdue": 3035, "startDate": "2017-01", "lastUpdate": "2020-06-18", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02998099", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02998099?tab=results", "prov": "prov:a77345003792b366" }, { "nctId": "NCT02626234", "title": "A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors", "sponsor": "Novartis Pharmaceuticals", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-02-28", "primaryCompletionType": "ACTUAL", "deadline": "2018-02-28", "daysOverdue": 3035, "startDate": "2015-12-08", "lastUpdate": "2020-12-10", "conditions": [ "cMET-dysregulated Advanced Solid Tumors" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02626234", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02626234?tab=results", "ticker": "NVS", "cik": "0001114448", "issuer": "NOVARTIS AG", "tickerConfidence": 0.95, "prov": "prov:4880cd0a097514d2" }, { "nctId": "NCT03054194", "title": "Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730", "sponsor": "Eisai Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-03-02", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-02", "daysOverdue": 3033, "startDate": "2017-01-31", "lastUpdate": "2018-09-07", "conditions": [ "Healthy Participants" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03054194", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03054194?tab=results", "prov": "prov:a9a1e9e1cb64a2cf" }, { "nctId": "NCT04253704", "title": "Effects of 2% IDL Lotion on Skin Hydration and Transepidermal Water Loss in Females With Dry Skin", "sponsor": "Shyla Cantor", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1", "PHASE2" ], "status": "COMPLETED", "primaryCompletion": "2017-03-03", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-03", "daysOverdue": 3032, "startDate": "2017-02-13", "lastUpdate": "2020-02-05", "conditions": [ "Xerosis Cutis" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT04253704", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT04253704?tab=results", "prov": "prov:b920f3229293100d" }, { "nctId": "NCT02889367", "title": "A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants", "sponsor": "Janssen Research & Development, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-03-04", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-04", "daysOverdue": 3031, "startDate": "2016-09-12", "lastUpdate": "2017-04-10", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02889367", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02889367?tab=results", "prov": "prov:b7e09442d7f4f8c6" }, { "nctId": "NCT02244489", "title": "Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma", "sponsor": "Sierra Oncology LLC - a GSK company", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-03-08", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-08", "daysOverdue": 3027, "startDate": "2014-11-05", "lastUpdate": "2019-02-01", "conditions": [ "Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02244489", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02244489?tab=results", "prov": "prov:26065552b012438a" }, { "nctId": "NCT03047317", "title": "A Pharmacokinetic Study of MABp1 in Healthy Volunteers", "sponsor": "Janssen Research & Development, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-03-08", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-08", "daysOverdue": 3027, "startDate": "2017-02-15", "lastUpdate": "2021-02-16", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03047317", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03047317?tab=results", "prov": "prov:dd3ec6b955c8475b" }, { "nctId": "NCT03044873", "title": "Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin", "sponsor": "Bristol-Myers Squibb", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-03-14", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-14", "daysOverdue": 3021, "startDate": "2017-02-02", "lastUpdate": "2017-04-17", "conditions": [ "Autoimmune Diseases", "Inflammatory Diseases" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03044873", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03044873?tab=results", "ticker": "BMY", "cik": "0000014272", "issuer": "BRISTOL MYERS SQUIBB CO", "tickerConfidence": 0.95, "prov": "prov:aed8d137ab7c9681" }, { "nctId": "NCT02991261", "title": "Bioavailability Study of SPARC001 (Study 2) in Healthy Adult Volunteers", "sponsor": "Sun Pharma Advanced Research Company Limited", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-03-15", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-15", "daysOverdue": 3020, "startDate": "2017-02-06", "lastUpdate": "2019-05-03", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02991261", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02991261?tab=results", "prov": "prov:504671f215f1adfd" }, { "nctId": "NCT02576457", "title": "Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis", "sponsor": "Bristol-Myers Squibb", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-03-15", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-15", "daysOverdue": 3020, "startDate": "2015-12-02", "lastUpdate": "2017-09-15", "conditions": [ "Severe Sepsis", "Septic Shock" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02576457", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02576457?tab=results", "ticker": "BMY", "cik": "0000014272", "issuer": "BRISTOL MYERS SQUIBB CO", "tickerConfidence": 0.95, "prov": "prov:1fa3c70ed6cc9ed9" }, { "nctId": "NCT02593851", "title": "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection", "sponsor": "Janssen Sciences Ireland UC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-03-21", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-21", "daysOverdue": 3014, "startDate": "2015-12-04", "lastUpdate": "2019-12-06", "conditions": [ "Respiratory Syncytial Virus Infections", "Virus Diseases" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02593851", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02593851?tab=results", "prov": "prov:110a69465b5632af" }, { "nctId": "NCT02882009", "title": "A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants", "sponsor": "Hoffmann-La Roche", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-03-22", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-22", "daysOverdue": 3013, "startDate": "2016-08-31", "lastUpdate": "2019-06-11", "conditions": [ "Healthy Volunteer" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02882009", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02882009?tab=results", "prov": "prov:0b94f05b5b3a5ef7" }, { "nctId": "NCT04320173", "title": "Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects", "sponsor": "Scilex Pharmaceuticals, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-03-22", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-22", "daysOverdue": 3013, "startDate": "2017-02-14", "lastUpdate": "2020-03-24", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT04320173", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT04320173?tab=results", "ticker": "SCLX", "cik": "0001820190", "issuer": "Scilex Holding Co", "tickerConfidence": 0.95, "prov": "prov:436af01d197e0ba7" }, { "nctId": "NCT02439346", "title": "Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel", "sponsor": "Bayer", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-03-27", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-27", "daysOverdue": 3008, "startDate": "2015-06-15", "lastUpdate": "2018-03-07", "conditions": [ "Medical Oncology" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02439346", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02439346?tab=results", "prov": "prov:f403870be65e57d8" }, { "nctId": "NCT02593760", "title": "A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)", "sponsor": "Hoffmann-La Roche", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-03-29", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-29", "daysOverdue": 3006, "startDate": "2016-01-25", "lastUpdate": "2018-05-11", "conditions": [ "Myelofibrosis" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02593760", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02593760?tab=results", "prov": "prov:8bdf064d643b2691" }, { "nctId": "NCT03058822", "title": "Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial", "sponsor": "Bristol-Myers Squibb", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-03-30", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-30", "daysOverdue": 3005, "startDate": "2017-01-25", "lastUpdate": "2017-12-20", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03058822", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03058822?tab=results", "ticker": "BMY", "cik": "0000014272", "issuer": "BRISTOL MYERS SQUIBB CO", "tickerConfidence": 0.95, "prov": "prov:6e1c7492e9c0c61a" }, { "nctId": "NCT03138759", "title": "Effect of Probenecid on Pexidartinib Pharmacokinetics", "sponsor": "Daiichi Sankyo", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-03-30", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-30", "daysOverdue": 3005, "startDate": "2017-02-27", "lastUpdate": "2017-05-03", "conditions": [ "Pharmacokinetics in Healthy Volunteers" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03138759", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03138759?tab=results", "prov": "prov:f3a4011c4fbdf751" }, { "nctId": "NCT03094403", "title": "To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel", "sponsor": "Sun Pharmaceutical Industries, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-03-31", "primaryCompletionType": "ACTUAL", "deadline": "2018-03-31", "daysOverdue": 3004, "startDate": "2016-07-01", "lastUpdate": "2024-04-10", "conditions": [ "Rosacea" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03094403", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03094403?tab=results", "prov": "prov:e1a2569d065cd491" }, { "nctId": "NCT04402112", "title": "Efficacy and Safety of Pitavastatin in a Real-world Setting", "sponsor": "JW Pharmaceutical", "sponsorClass": "INDUSTRY", "phases": [], "status": "COMPLETED", "primaryCompletion": "2017-04-01", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-01", "daysOverdue": 3003, "startDate": "2012-04-02", "lastUpdate": "2021-04-19", "conditions": [ "Hypercholesterolemia" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT04402112", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT04402112?tab=results", "prov": "prov:3848c768941ff949" }, { "nctId": "NCT03158506", "title": "Human Mass Balance Study of HMS5552 in Healthy Subjects", "sponsor": "Hua Medicine Limited", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-06", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-06", "daysOverdue": 2998, "startDate": "2017-03-29", "lastUpdate": "2018-12-31", "conditions": [ "Healthy Subject" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03158506", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03158506?tab=results", "prov": "prov:54cd1e11da1240af" }, { "nctId": "NCT02920398", "title": "A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A", "sponsor": "Novo Nordisk A/S", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-07", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-07", "daysOverdue": 2997, "startDate": "2016-10-04", "lastUpdate": "2017-12-15", "conditions": [ "Congenital Bleeding Disorder", "Haemophilia A" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02920398", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02920398?tab=results", "ticker": "NVO", "cik": "0000353278", "issuer": "NOVO NORDISK A S", "tickerConfidence": 0.95, "prov": "prov:87822ff289af9538" }, { "nctId": "NCT03063645", "title": "Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production", "sponsor": "Cerecin", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-07", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-07", "daysOverdue": 2997, "startDate": "2017-03-11", "lastUpdate": "2017-06-27", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03063645", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03063645?tab=results", "prov": "prov:54f7163c1fb64136" }, { "nctId": "NCT02709850", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia", "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-12", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-12", "daysOverdue": 2992, "startDate": "2015-11-30", "lastUpdate": "2020-11-19", "conditions": [ "Hypertriglyceridemia", "Familial Hypercholesterolemia" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02709850", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02709850?tab=results", "ticker": "IONS", "cik": "0000874015", "issuer": "IONIS PHARMACEUTICALS INC", "tickerConfidence": 0.95, "prov": "prov:064b5993e0759924" }, { "nctId": "NCT02696148", "title": "A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years", "sponsor": "Novo Nordisk A/S", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-13", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-13", "daysOverdue": 2991, "startDate": "2016-03-14", "lastUpdate": "2019-03-18", "conditions": [ "Metabolism and Nutrition Disorder", "Obesity" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02696148", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02696148?tab=results", "ticker": "NVO", "cik": "0000353278", "issuer": "NOVO NORDISK A S", "tickerConfidence": 0.95, "prov": "prov:eb4bafe3999e8daf" }, { "nctId": "NCT03643627", "title": "A Study of SYNT001 in Healthy Volunteers", "sponsor": "Syntimmune, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "EARLY_PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-13", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-13", "daysOverdue": 2991, "startDate": "2016-08-17", "lastUpdate": "2018-08-24", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03643627", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03643627?tab=results", "prov": "prov:f28ba45839d2dbd2" }, { "nctId": "NCT00833963", "title": "A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine", "sponsor": "Genentech, Inc.", "sponsorClass": "INDUSTRY", "phases": [], "status": "COMPLETED", "primaryCompletion": "2017-04-13", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-13", "daysOverdue": 2991, "startDate": "2009-01-14", "lastUpdate": "2019-05-16", "conditions": [ "Breast Cancer", "Pregnancy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT00833963", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT00833963?tab=results", "prov": "prov:4aca71f6a22c9a20" }, { "nctId": "NCT01949324", "title": "A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel", "sponsor": "Neurotech Pharmaceuticals", "sponsorClass": "INDUSTRY", "phases": [ "PHASE2" ], "status": "COMPLETED", "primaryCompletion": "2017-04-14", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-14", "daysOverdue": 2990, "startDate": "2014-04", "lastUpdate": "2018-09-12", "conditions": [ "Macular Telangiectasia Type 2" ], "fdaDrug": true, "fdaDevice": true, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT01949324", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT01949324?tab=results", "prov": "prov:7f02e0b5b9291933" }, { "nctId": "NCT02524782", "title": "A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes", "sponsor": "MedImmune LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-14", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-14", "daysOverdue": 2990, "startDate": "2015-10-07", "lastUpdate": "2019-03-13", "conditions": [ "Type 2 Diabetes" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02524782", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02524782?tab=results", "prov": "prov:69b7ea111cc28c9f" }, { "nctId": "NCT04163783", "title": "Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males", "sponsor": "BeiGene", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-18", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-18", "daysOverdue": 2986, "startDate": "2017-03-29", "lastUpdate": "2019-11-15", "conditions": [ "Healthy Volunteers" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT04163783", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT04163783?tab=results", "prov": "prov:fd0e126f35a3bb74" }, { "nctId": "NCT03070678", "title": "Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects", "sponsor": "Sanofi", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-18", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-18", "daysOverdue": 2986, "startDate": "2017-03-14", "lastUpdate": "2022-04-25", "conditions": [ "Diabetes Mellitus" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03070678", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03070678?tab=results", "ticker": "SNY", "cik": "0001121404", "issuer": "Sanofi", "tickerConfidence": 0.95, "prov": "prov:f026ecd26b4f412a" }, { "nctId": "NCT03059303", "title": "Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)", "sponsor": "Janssen Research & Development, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-04-24", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-24", "daysOverdue": 2980, "startDate": "2017-02-20", "lastUpdate": "2017-12-22", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03059303", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03059303?tab=results", "prov": "prov:3ea98f29792f43ec" }, { "nctId": "NCT03931993", "title": "A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL", "sponsor": "Allergy Therapeutics", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-27", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-27", "daysOverdue": 2977, "startDate": "2017-01-16", "lastUpdate": "2019-04-30", "conditions": [ "Seasonal Allergic Rhinitis" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03931993", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03931993?tab=results", "prov": "prov:d141834239b7ab57" }, { "nctId": "NCT03480997", "title": "Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD", "sponsor": "Pneuma Respiratory, Inc", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04-28", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-28", "daysOverdue": 2976, "startDate": "2016-12-27", "lastUpdate": "2018-03-29", "conditions": [ "COPD" ], "fdaDrug": true, "fdaDevice": true, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03480997", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03480997?tab=results", "prov": "prov:bb4f223d7c1da7d1" }, { "nctId": "NCT02138812", "title": "Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel", "sponsor": "Bayer", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-04-28", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-28", "daysOverdue": 2976, "startDate": "2014-05-09", "lastUpdate": "2018-10-12", "conditions": [ "Medical Oncology" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02138812", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02138812?tab=results", "prov": "prov:70064ded3dfb4a82" }, { "nctId": "NCT03038971", "title": "Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections", "sponsor": "Woodmont Pharmaceuticals, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-04-29", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-29", "daysOverdue": 2975, "startDate": "2017-03-30", "lastUpdate": "2018-02-26", "conditions": [ "Allergic Conjunctivitis", "Allergic Rhinitis" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03038971", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03038971?tab=results", "prov": "prov:5a8956eb41fc8f21" }, { "nctId": "NCT03168035", "title": "Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma", "sponsor": "NanoCarrier Co., Ltd.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-04", "primaryCompletionType": "ACTUAL", "deadline": "2018-04-30", "daysOverdue": 2974, "startDate": "2013-11", "lastUpdate": "2018-02-23", "conditions": [ "Advanced Cancer", "Lymphoma" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03168035", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03168035?tab=results", "prov": "prov:42125e64b19663d8" }, { "nctId": "NCT03107013", "title": "A Study to Investigate the Mass Balance of BTD-001", "sponsor": "Balance Therapeutics", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-01", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-01", "daysOverdue": 2973, "startDate": "2017-04-03", "lastUpdate": "2017-10-24", "conditions": [ "Molecular Mechanisms of Pharmacological Action" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03107013", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03107013?tab=results", "prov": "prov:8cde187939869102" }, { "nctId": "NCT01653470", "title": "Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors", "sponsor": "Bristol-Myers Squibb", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-03", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-03", "daysOverdue": 2971, "startDate": "2012-10-12", "lastUpdate": "2020-01-28", "conditions": [ "Cancer" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT01653470", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT01653470?tab=results", "ticker": "BMY", "cik": "0000014272", "issuer": "BRISTOL MYERS SQUIBB CO", "tickerConfidence": 0.95, "prov": "prov:96fa5d895c549f4b" }, { "nctId": "NCT03121339", "title": "Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults", "sponsor": "Vaxart", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-05", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-05", "daysOverdue": 2969, "startDate": "2017-03-31", "lastUpdate": "2018-05-30", "conditions": [ "Seasonal Influenza Preventative Vaccine Pharmacodynamics" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03121339", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03121339?tab=results", "ticker": "VXRT", "cik": "0000072444", "issuer": "Vaxart, Inc.", "tickerConfidence": 0.95, "prov": "prov:1443ff7b9fcb145f" }, { "nctId": "NCT03071770", "title": "Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects", "sponsor": "Agios Pharmaceuticals, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-09", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-09", "daysOverdue": 2965, "startDate": "2017-03-31", "lastUpdate": "2018-01-11", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03071770", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03071770?tab=results", "ticker": "AGIO", "cik": "0001439222", "issuer": "AGIOS PHARMACEUTICALS, INC.", "tickerConfidence": 0.95, "prov": "prov:6d4bb2784d8ccf2a" }, { "nctId": "NCT03063580", "title": "Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin", "sponsor": "Sanofi", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-12", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-12", "daysOverdue": 2962, "startDate": "2017-02-27", "lastUpdate": "2022-04-25", "conditions": [ "Diabetes Mellitus" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03063580", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03063580?tab=results", "ticker": "SNY", "cik": "0001121404", "issuer": "Sanofi", "tickerConfidence": 0.95, "prov": "prov:f8cfbca7c3b28d20" }, { "nctId": "NCT03082300", "title": "A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations", "sponsor": "Astellas Pharma Global Development, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-05-12", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-12", "daysOverdue": 2962, "startDate": "2017-03-24", "lastUpdate": "2024-11-20", "conditions": [ "Non-small Cell Lung Cancer (NSCLC)", "Epidermal Growth Factor Receptor (EGFR) Mutations" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03082300", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03082300?tab=results", "prov": "prov:6dc893c028b9bdd2" }, { "nctId": "NCT03098953", "title": "Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations", "sponsor": "Bausch & Lomb Incorporated", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-12", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-12", "daysOverdue": 2962, "startDate": "2017-04-10", "lastUpdate": "2017-05-18", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03098953", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03098953?tab=results", "ticker": "BLCO", "cik": "0001860742", "issuer": "Bausch & Lomb Corp", "tickerConfidence": 0.8166666666666667, "prov": "prov:2cb25e0db8b396a7" }, { "nctId": "NCT03066687", "title": "A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants", "sponsor": "Janssen Research & Development, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-12", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-12", "daysOverdue": 2962, "startDate": "2017-03-14", "lastUpdate": "2017-06-23", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03066687", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03066687?tab=results", "prov": "prov:727e77b0e93123ce" }, { "nctId": "NCT04039958", "title": "A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)", "sponsor": "Genuine Research Center, Egypt", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-13", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-13", "daysOverdue": 2961, "startDate": "2017-04-05", "lastUpdate": "2019-07-31", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT04039958", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT04039958?tab=results", "prov": "prov:ba7c02ce7d7c0d05" }, { "nctId": "NCT01473901", "title": "A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma", "sponsor": "Novartis Pharmaceuticals", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-17", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-17", "daysOverdue": 2957, "startDate": "2011-12-30", "lastUpdate": "2020-12-09", "conditions": [ "Glioblastoma" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT01473901", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT01473901?tab=results", "ticker": "NVS", "cik": "0001114448", "issuer": "NOVARTIS AG", "tickerConfidence": 0.95, "prov": "prov:fe59af207b17aea9" }, { "nctId": "NCT04032834", "title": "A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects", "sponsor": "Vectura Limited", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-22", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-22", "daysOverdue": 2952, "startDate": "2017-02-20", "lastUpdate": "2019-07-25", "conditions": [ "Asthma" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT04032834", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT04032834?tab=results", "prov": "prov:56cd9948a40db5ed" }, { "nctId": "NCT03198676", "title": "A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production", "sponsor": "Prep Biopharm Limited", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-24", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-24", "daysOverdue": 2950, "startDate": "2017-05-08", "lastUpdate": "2017-07-02", "conditions": [ "Upper Respiratory Tract Infections" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03198676", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03198676?tab=results", "prov": "prov:88534b7e44e7b932" }, { "nctId": "NCT03161015", "title": "Single-Dose PK Study of GBT440 in Subjects With Renal Impairment", "sponsor": "Global Blood Therapeutics", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-25", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-25", "daysOverdue": 2949, "startDate": "2016-11", "lastUpdate": "2018-02-22", "conditions": [ "Renal Impairment" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03161015", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03161015?tab=results", "prov": "prov:256bbd7183022416" }, { "nctId": "NCT02993237", "title": "Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets", "sponsor": "Janssen Research & Development, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05-25", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-25", "daysOverdue": 2949, "startDate": "2017-01-23", "lastUpdate": "2019-05-13", "conditions": [ "HIV-1" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02993237", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02993237?tab=results", "prov": "prov:828fd9d4e8053536" }, { "nctId": "NCT03126097", "title": "A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females", "sponsor": "Janssen Research & Development, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-05-26", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-26", "daysOverdue": 2948, "startDate": "2017-04-13", "lastUpdate": "2017-09-01", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03126097", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03126097?tab=results", "prov": "prov:1d6e5cdbcf80069f" }, { "nctId": "NCT02480374", "title": "Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer", "sponsor": "Imunon", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-31", "daysOverdue": 2943, "startDate": "2015-09", "lastUpdate": "2024-10-02", "conditions": [ "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02480374", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02480374?tab=results", "ticker": "IMNN", "cik": "0000749647", "issuer": "Imunon, Inc.", "tickerConfidence": 0.95, "prov": "prov:31d186e3a152c64f" }, { "nctId": "NCT02860650", "title": "A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults", "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-05", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-31", "daysOverdue": 2943, "startDate": "2016-08", "lastUpdate": "2018-02-05", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02860650", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02860650?tab=results", "prov": "prov:23c3cbf75c3672c7" }, { "nctId": "NCT03146013", "title": "Dual Algorithm Post Market Clinical Study", "sponsor": "MP Biomedicals, LLC", "sponsorClass": "INDUSTRY", "phases": [], "status": "COMPLETED", "primaryCompletion": "2017-05-31", "primaryCompletionType": "ACTUAL", "deadline": "2018-05-31", "daysOverdue": 2943, "startDate": "2017-03-01", "lastUpdate": "2017-06-12", "conditions": [ "HTLV-I Infections", "HTLV-II Infections", "Human T-lymphotropic Virus 1", "Human T-lymphotropic Virus 2", "HTLV I Associated T Cell Leukemia Lymphoma", "HTLV I Associated Myelopathies" ], "fdaDrug": true, "fdaDevice": true, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03146013", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03146013?tab=results", "prov": "prov:57702f2efcc7e640" }, { "nctId": "NCT03187496", "title": "Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.", "sponsor": "Enanta Pharmaceuticals, Inc", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-01", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-01", "daysOverdue": 2942, "startDate": "2017-05-11", "lastUpdate": "2017-08-21", "conditions": [ "NASH" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03187496", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03187496?tab=results", "ticker": "ENTA", "cik": "0001177648", "issuer": "ENANTA PHARMACEUTICALS INC", "tickerConfidence": 0.95, "prov": "prov:a548fcaacf97ea22" }, { "nctId": "NCT05341102", "title": "A Study of Single and Repeated Doses of LY3556050 in Healthy Participants", "sponsor": "Eli Lilly and Company", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-02", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-02", "daysOverdue": 2941, "startDate": "2016-09-14", "lastUpdate": "2022-04-22", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT05341102", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT05341102?tab=results", "ticker": "LLY", "cik": "0000059478", "issuer": "ELI LILLY & Co", "tickerConfidence": 0.8166666666666667, "prov": "prov:354a414948c55db4" }, { "nctId": "NCT03206229", "title": "Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects", "sponsor": "Adello Biologics, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-02", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-02", "daysOverdue": 2941, "startDate": "2017-02-13", "lastUpdate": "2018-07-03", "conditions": [ "Healthy Volunteers" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03206229", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03206229?tab=results", "prov": "prov:2a8eb6f874eb3766" }, { "nctId": "NCT03108274", "title": "A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants", "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-02", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-02", "daysOverdue": 2941, "startDate": "2017-04-18", "lastUpdate": "2021-06-24", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03108274", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03108274?tab=results", "prov": "prov:1d260084ee0e0a26" }, { "nctId": "NCT03187015", "title": "A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects", "sponsor": "Syndax Pharmaceuticals", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-04", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-04", "daysOverdue": 2939, "startDate": "2017-05-23", "lastUpdate": "2018-08-16", "conditions": [ "Drug Interaction", "Healthy Volunteer" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03187015", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03187015?tab=results", "ticker": "SNDX", "cik": "0001395937", "issuer": "Syndax Pharmaceuticals Inc", "tickerConfidence": 0.95, "prov": "prov:b4c511c126b2f324" }, { "nctId": "NCT03554304", "title": "Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers", "sponsor": "Wockhardt", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-05", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-05", "daysOverdue": 2938, "startDate": "2017-02-09", "lastUpdate": "2018-06-13", "conditions": [ "QT/QTc Interval in Healthy Volunteers" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03554304", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03554304?tab=results", "prov": "prov:c585576896930400" }, { "nctId": "NCT03046459", "title": "A First-in-Human Study of BNZ132-1-40", "sponsor": "Bioniz Therapeutics", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-05", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-05", "daysOverdue": 2938, "startDate": "2016-11", "lastUpdate": "2017-06-22", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03046459", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03046459?tab=results", "prov": "prov:38de667c6d7d983b" }, { "nctId": "NCT02286219", "title": "Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)", "sponsor": "Bristol-Myers Squibb", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-08", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-08", "daysOverdue": 2935, "startDate": "2014-11-04", "lastUpdate": "2017-09-18", "conditions": [ "Solid Tumors That Overexpress HER2 (HER2 Positive)" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02286219", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02286219?tab=results", "ticker": "BMY", "cik": "0000014272", "issuer": "BRISTOL MYERS SQUIBB CO", "tickerConfidence": 0.95, "prov": "prov:5a3eef244f35d25d" }, { "nctId": "NCT03329014", "title": "A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability", "sponsor": "Paion UK Ltd.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-09", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-09", "daysOverdue": 2934, "startDate": "2017-05-15", "lastUpdate": "2019-04-04", "conditions": [ "Procedural Sedation" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03329014", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03329014?tab=results", "prov": "prov:a49a64e20f96519c" }, { "nctId": "NCT01862081", "title": "A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer", "sponsor": "Genentech, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-09", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-09", "daysOverdue": 2934, "startDate": "2013-07-16", "lastUpdate": "2017-11-28", "conditions": [ "Breast Cancer, Non-small Lung Cancer" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT01862081", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT01862081?tab=results", "prov": "prov:743bcd53ae588d94" }, { "nctId": "NCT02866227", "title": "TOL-463 Phase 2 Study for Vaginitis", "sponsor": "Toltec Pharmaceuticals, LLC", "sponsorClass": "INDUSTRY", "phases": [ "PHASE2" ], "status": "COMPLETED", "primaryCompletion": "2017-06-10", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-10", "daysOverdue": 2933, "startDate": "2016-07-15", "lastUpdate": "2018-03-09", "conditions": [ "Bacterial Vaginosis", "Vulvovaginal Candidiasis" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02866227", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02866227?tab=results", "prov": "prov:d00e6ec41c25c676" }, { "nctId": "NCT03229291", "title": "A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects", "sponsor": "Biosplice Therapeutics, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-11", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-11", "daysOverdue": 2932, "startDate": "2016-11-03", "lastUpdate": "2017-07-25", "conditions": [ "Tendinopathy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03229291", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03229291?tab=results", "prov": "prov:22fdff271a6bbf0c" }, { "nctId": "NCT03020784", "title": "Safety and Tolerability of PF-06818883 in Healthy Subjects", "sponsor": "Pfizer", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-06-13", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-13", "daysOverdue": 2930, "startDate": "2016-11-11", "lastUpdate": "2017-12-11", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03020784", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03020784?tab=results", "ticker": "PFE", "cik": "0000078003", "issuer": "PFIZER INC", "tickerConfidence": 0.95, "prov": "prov:f5ffd9bde46b9f99" }, { "nctId": "NCT05873907", "title": "A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants", "sponsor": "Amgen", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-16", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-16", "daysOverdue": 2927, "startDate": "2015-10-19", "lastUpdate": "2023-05-24", "conditions": [ "Chronic Graft-versus-host Disease (cGVHD)" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT05873907", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT05873907?tab=results", "ticker": "AMGN", "cik": "0000318154", "issuer": "AMGEN INC", "tickerConfidence": 0.95, "prov": "prov:eef2dfba93257b1c" }, { "nctId": "NCT02941354", "title": "Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A", "sponsor": "Novo Nordisk A/S", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-20", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-20", "daysOverdue": 2923, "startDate": "2016-10-10", "lastUpdate": "2019-01-30", "conditions": [ "Congenital Bleeding Disorder", "Haemophilia A" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02941354", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02941354?tab=results", "ticker": "NVO", "cik": "0000353278", "issuer": "NOVO NORDISK A S", "tickerConfidence": 0.95, "prov": "prov:3afbde101c0e480e" }, { "nctId": "NCT02143635", "title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt", "sponsor": "Novartis Pharmaceuticals", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-20", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-20", "daysOverdue": 2923, "startDate": "2014-07-07", "lastUpdate": "2021-05-21", "conditions": [ "Advanced Solid and Hematological TP53wt Tumors" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02143635", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02143635?tab=results", "ticker": "NVS", "cik": "0001114448", "issuer": "NOVARTIS AG", "tickerConfidence": 0.95, "prov": "prov:484a0619c721b99e" }, { "nctId": "NCT01292655", "title": "Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors", "sponsor": "Bristol-Myers Squibb", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-22", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-22", "daysOverdue": 2921, "startDate": "2011-03-03", "lastUpdate": "2020-01-27", "conditions": [ "Cancer" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT01292655", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT01292655?tab=results", "ticker": "BMY", "cik": "0000014272", "issuer": "BRISTOL MYERS SQUIBB CO", "tickerConfidence": 0.95, "prov": "prov:b03bece843369016" }, { "nctId": "NCT03174041", "title": "A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin", "sponsor": "Genentech, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-23", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-23", "daysOverdue": 2920, "startDate": "2017-04-18", "lastUpdate": "2019-09-24", "conditions": [ "Healthy Participants" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03174041", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03174041?tab=results", "prov": "prov:5a5fa114a764b9c3" }, { "nctId": "NCT03327558", "title": "Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects", "sponsor": "Bausch Health Americas, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-23", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-23", "daysOverdue": 2920, "startDate": "2017-05-15", "lastUpdate": "2018-05-08", "conditions": [ "Ulcerative Colitis" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03327558", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03327558?tab=results", "ticker": "BHC", "cik": "0000885590", "issuer": "Bausch Health Companies Inc.", "tickerConfidence": 0.8166666666666667, "prov": "prov:96aa08762644d8e5" }, { "nctId": "NCT03257943", "title": "A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%", "sponsor": "Sun Pharmaceutical Industries, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-27", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-27", "daysOverdue": 2916, "startDate": "2017-03-20", "lastUpdate": "2018-05-18", "conditions": [ "Lice; Head Lice" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03257943", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03257943?tab=results", "prov": "prov:deec10993be8b6b6" }, { "nctId": "NCT03032536", "title": "Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers", "sponsor": "Alios Biopharma Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "TERMINATED", "primaryCompletion": "2017-06-28", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-28", "daysOverdue": 2915, "startDate": "2017-01-31", "lastUpdate": "2017-10-16", "conditions": [ "Hepatitis B", "Chronic Hepatitis B", "Viral Hepatitis B" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03032536", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03032536?tab=results", "prov": "prov:b209f017bded1ffe" }, { "nctId": "NCT03135509", "title": "A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects", "sponsor": "Celgene", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-28", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-28", "daysOverdue": 2915, "startDate": "2017-05-24", "lastUpdate": "2017-07-02", "conditions": [ "Healthy Volunteers" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03135509", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03135509?tab=results", "prov": "prov:44d42483382adc0f" }, { "nctId": "NCT02223247", "title": "A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors", "sponsor": "Sagimet Biosciences Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-30", "daysOverdue": 2913, "startDate": "2013-11", "lastUpdate": "2017-08-14", "conditions": [ "Solid Malignant Tumor" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02223247", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02223247?tab=results", "ticker": "SGMT", "cik": "0001400118", "issuer": "Sagimet Biosciences Inc.", "tickerConfidence": 0.95, "prov": "prov:916ee7c1433ecc2e" }, { "nctId": "NCT02475447", "title": "Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis", "sponsor": "Tioga Pharmaceuticals", "sponsorClass": "INDUSTRY", "phases": [ "PHASE2" ], "status": "COMPLETED", "primaryCompletion": "2017-06", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-30", "daysOverdue": 2913, "startDate": "2015-07", "lastUpdate": "2017-12-13", "conditions": [ "Pruritus", "Atopic Dermatitis" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT02475447", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT02475447?tab=results", "prov": "prov:965805521f1ede06" }, { "nctId": "NCT03630094", "title": "Plasma and Intrapulmonary Concentrations Study of WCK 5222", "sponsor": "Wockhardt", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-06-30", "primaryCompletionType": "ACTUAL", "deadline": "2018-06-30", "daysOverdue": 2913, "startDate": "2017-03-31", "lastUpdate": "2018-08-14", "conditions": [ "PHA1A" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03630094", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03630094?tab=results", "prov": "prov:1eee219b3fd8dce1" }, { "nctId": "NCT03125473", "title": "Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers", "sponsor": "Vaxart", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-07-01", "primaryCompletionType": "ACTUAL", "deadline": "2018-07-01", "daysOverdue": 2912, "startDate": "2017-04-07", "lastUpdate": "2018-05-30", "conditions": [ "Norovirus Gastroenteritis" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03125473", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03125473?tab=results", "ticker": "VXRT", "cik": "0000072444", "issuer": "Vaxart, Inc.", "tickerConfidence": 0.95, "prov": "prov:1d1a1ebf9bb8bc2a" }, { "nctId": "NCT03234699", "title": "Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions", "sponsor": "SK Life Science, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-07-03", "primaryCompletionType": "ACTUAL", "deadline": "2018-07-03", "daysOverdue": 2910, "startDate": "2017-02-22", "lastUpdate": "2024-09-19", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03234699", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03234699?tab=results", "prov": "prov:6825a29c6c2d835a" }, { "nctId": "NCT01324479", "title": "Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors", "sponsor": "Novartis Pharmaceuticals", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-07-04", "primaryCompletionType": "ACTUAL", "deadline": "2018-07-04", "daysOverdue": 2909, "startDate": "2012-02-29", "lastUpdate": "2020-12-19", "conditions": [ "Solid Tumors" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT01324479", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT01324479?tab=results", "ticker": "NVS", "cik": "0001114448", "issuer": "NOVARTIS AG", "tickerConfidence": 0.95, "prov": "prov:65aa556c9e0bc457" }, { "nctId": "NCT03130556", "title": "A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation", "sponsor": "Pfizer", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-07-06", "primaryCompletionType": "ACTUAL", "deadline": "2018-07-06", "daysOverdue": 2907, "startDate": "2017-05-01", "lastUpdate": "2017-08-01", "conditions": [ "Healthy Volunteers" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03130556", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03130556?tab=results", "ticker": "PFE", "cik": "0000078003", "issuer": "PFIZER INC", "tickerConfidence": 0.95, "prov": "prov:ddbad7b8ad73b7e8" }, { "nctId": "NCT03065556", "title": "A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)", "sponsor": "Therapeutics, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE2" ], "status": "COMPLETED", "primaryCompletion": "2017-07-06", "primaryCompletionType": "ACTUAL", "deadline": "2018-07-06", "daysOverdue": 2907, "startDate": "2017-01-26", "lastUpdate": "2018-08-10", "conditions": [ "Plaque Psoriasis" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03065556", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03065556?tab=results", "prov": "prov:21e7b26e26596dae" }, { "nctId": "NCT03177278", "title": "A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin", "sponsor": "Achaogen, Inc.", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-07-10", "primaryCompletionType": "ACTUAL", "deadline": "2018-07-10", "daysOverdue": 2903, "startDate": "2017-06-16", "lastUpdate": "2017-07-12", "conditions": [ "Healthy Volunteers" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03177278", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03177278?tab=results", "prov": "prov:0c2383d906d0d2fb" }, { "nctId": "NCT03126721", "title": "The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults", "sponsor": "Pfizer", "sponsorClass": "INDUSTRY", "phases": [ "PHASE1" ], "status": "COMPLETED", "primaryCompletion": "2017-07-11", "primaryCompletionType": "ACTUAL", "deadline": "2018-07-11", "daysOverdue": 2902, "startDate": "2017-04-18", "lastUpdate": "2017-07-26", "conditions": [ "Healthy" ], "fdaDrug": true, "fdaDevice": false, "resultsPosted": false, "ctgovUrl": "https://clinicaltrials.gov/study/NCT03126721", "ctgovResultsUrl": "https://clinicaltrials.gov/study/NCT03126721?tab=results", "ticker": "PFE", "cik": "0000078003", "issuer": "PFIZER INC", "tickerConfidence": 0.95, "prov": "prov:8a61d8ae7003ec8b" } ], "disclaimer": "Public-record facts derived from ClinicalTrials.gov. NOT a finding of violation, fraud, or non-compliance. NOT legal/investment advice." }